Additionally, we demonstrate that dual targeting of AKT with the allosteric pan-AKT inhibitor MK-2206 and mTOR using the mTORC1/mTORC2 bi-specific ATP-competitor AZD8055 is sufficient to significantly decrease NF1-null MPNST cell viability in vitro. The gene discussed is MTOR; the disease is malignant peripheral nerve sheath tumor.